Biosig Technologies (NASDAQ:STEX) Major Shareholder Frank Giustra Acquires 1,000,000 Shares of Stock

Biosig Technologies, Inc. (NASDAQ:STEX) major shareholder Frank Giustra acquired 1,000,000 shares of the company’s stock in a transaction dated Friday, January 23rd. The stock was acquired at an average price of $3.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the insider directly owned 1,178,205 shares of the company’s stock, valued at $3,534,615. This trade represents a 561.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Biosig Technologies Stock Up 7.4%

STEX opened at $3.65 on Wednesday. Biosig Technologies, Inc. has a 12-month low of $0.40 and a 12-month high of $14.11.

Analysts Set New Price Targets

Separately, Weiss Ratings started coverage on shares of Biosig Technologies in a research note on Friday. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Biosig Technologies News Summary

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at $3.00 (≈$3.0M), increasing his direct stake to 1,178,205 shares — a large, confidence-signaling purchase disclosed to the SEC. SEC Filing
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares at ~$3.03, raising his holdings to ~1,051,511 shares — another insider buy that supports management confidence. SEC Filing
• Positive Sentiment: Director Morgan Lee Lekstrom executed multiple purchases (including 41,000 and 23,000-share transactions at ~\$3.13–\$3.30), materially increasing her stake — another insider buy pattern reinforcing insider conviction. SEC Filing
• Neutral Sentiment: Press releases show closings of public offerings tied to the STEX ticker (announcements reporting $35M and $40.25M gross proceeds). If these refer to the same issuer, proceeds increase liquidity but also imply share issuance/dilution — impact depends on use of proceeds and whether this is the same corporate entity. Globe Newswire
• Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” rating, and MarketBeat shows an average analyst view of “Sell” — negative third‑party sentiment that can cap upside despite insider buying. Weiss Ratings

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.